Ranbaxy

By: Punit Sahu

Content’s Introduction History Mission and Vision Values Life @ Ranbaxy Ranbaxy –Daiichi Sankyo Partnership Corporate Social Responsibility R & D Board of Director’s Ranbaxy's Top Products Global manufacturing strength Global sales Market shares & market review Contact us!!!!!

Introduction

Ranbaxy is the India's largest pharmaceutical company,

Incorporated in1961. Headquarters Located in Gurgaon,

Haryana,india.

The company went public in 1973, and Japanese company Daiichi Sankyo gained majority control in 2008. . Worldwide Presence

Ground presence in 46 countries, products sold in over 125 countries. Manufacturing locations in 7 countries.

Atul Sobti is currently Ranbaxy CEO and M.D., having taken over from Malvinder Singh in May 2009.

Cont… History of Ranbaxy

Ranbaxy was started by Ranbir Singh and Gurbax Singh in 1937 as a distributor for a Japanese company Shionogi.

The name Ranbaxy is a portmanteau word from the names of its first owners Ranbir and Gurbax.

Bhai Mohan Singh bought the company in 1952 and after that Mohan Singh and Shivinder Mohan Singh sold the company to the Japanese company

Daiichi Sankyo in June 2008.

CORPORATE OFFICECORPORATE OFFICE

Mission

To become a Research-based International Pharmaceutical Company

Vision –2012

Achieve significant businessin proprietary prescription products by 2012with a strong presence in developed markets

Aspirations –2012

•Aspire to be a $5 Billion Company•Become a Top 5 Global Generics Player

•Significant Income from Proprietary Products

•Achieving customer satisfaction is fundamental of business

•Provide products and services of the highest quality

•Practice dignity and equity in relationship and provide opportunities for our people to realise their full potential

•Ensure profitable growth and enhance wealth of the shareholders

•Foster mutually beneficial relations with all our business partners

•Manage our operations with high concern for safety and environment

•Be a responsible corporate citizen

value

Life @RanbaxyA career at Ranbaxy means an opportunity for ample learning & growth. A career at Ranbaxy means an opportunity for ample learning & growth. It offers avenues to work across the globe along side the finest minds. The It offers avenues to work across the globe along side the finest minds. The Company offers a challenging assignment, a world class working Company offers a challenging assignment, a world class working environment, professional management, competitive salaries, stock options environment, professional management, competitive salaries, stock options along with exceptional rewards.along with exceptional rewards.If you have an appetite for challenges, we have an exciting career for youIf you have an appetite for challenges, we have an exciting career for you

OpportunitiesOpportunities

The global spread of Ranbaxy and the blazing growth in business The global spread of Ranbaxy and the blazing growth in business provides ample opportunities for our employees to build careers in provides ample opportunities for our employees to build careers in various fields.various fields.Our managers will generally have the opportunity to live and Our managers will generally have the opportunity to live and work in different countries; such international experience will work in different countries; such international experience will help them better understand our complex business and grow help them better understand our complex business and grow both personally and professionally.both personally and professionally.

•A path breaking confluence that redefines the global pharma paradigm..

•Provides solutions to key need-gaps for each organization.

•Strategic combination creates an Innovator and Generic Pharmaceutical Powerhouse.

•Combined entity is ranked among the Top 20 global pharmaceutical companies

•Ranbaxy enters into a new orbit to chart a higher trajectory.

•Complementary strengths ranging from excellence in NDDR to extensive reach across globalmarkets.

•Financially & strategically beneficial for all stakeholders.

Ranbaxy –Daiichi Sankyo Partnership

Corporate Social ResponsibilityCREATING VALUE…VALUING LIFE…

• An essential component of Ranbaxy's CSR is

to care for the community.

• Based on the theme „Health For All‟ setupRanbaxy Rural Development Trust‟ in 1978; later re-christened as „Ranbaxy Community Health Care Society‟ in 1994.

• Operates in the states of Punjab, Haryana,

H.P.,MP.and Delhi /Gurgaon to provide

integrated health care to about 2 lakh peoplestaying in 100 villages and urban slum areas…..

Research & Development

Dr. Sudershan K. Arora (L)President - R&D (Generics, NDDS & Drug Development)Dr. Pradip Kumar Bhatnagar (R)Sr. Vice President, New Drug Discovery Research

State-of-the-art R&D facilitiesbased in India

R&D I R&D IIR&D III

R&D IV

Research & Development•Dedicated Facilities for Innovative & Generics Research

•1400 R&D Personnel ( ~ 300 Doctorates)

•Highest R&D spender across industry

•8 -10 NCE molecules in pipeline

•NDDS based products (4 platform technologies) •R&D collaborations

Alliance / Collaboration in NDDR

Out-licensingIn NDDS

Out-licensingIn NDDS

Alliance / Collaboration in NDDR

Chairman, CEO & M.D.Chairman, CEO & M.D.

Dr. Tsutomu Une Chairman

Malvinder Mohan SinghChairman, CEO & M. D.

Board of Directors

Dr. Tsutomu UneChairman Non Executive & Non Independent Director

Mr. Atul SobtiC E O & M D

Mr. Takashi ShodaNon Executive &Non Independent Director

Dr. Anthony H. WildIndependent Director

Mr. Rajesh V. ShahIndependent Director

Mr. Rajesh V. ShahIndependent Director

Mr. Percy ShroffIndependent Director

Ranbaxy’s Top Products

for the treatment of brain cancer, for the treatment of brain cancer, pancreatic cancerpancreatic cancer  

SimvastatinSimvastatin

control control hypercholesterolemia & to prevent cardiovascular disease

AmoxiClav PotassiumAmoxiClav PotassiumUsed to treat a broad-spectrum of bacterialUsed to treat a broad-spectrum of bacterial infections,infections,

IsotretinoinIsotretinoin

CiprofloxacinCiprofloxacin

It kills bacteria by interferingIt kills bacteria by interfering

OmeprazoleOmeprazole

used in the treatment of used in the treatment of dyspepsia

Developed Markets Presence

•Largest generic market worldwide•Significant patent expiries through 2011

•Germany, UK -mature markets •France, Spain, Italy, Romania -emerging markets•Ranbaxy has presence in 23 of the 27 EU countries

•Mature generic market•Ranbaxy is the fastest growing generics company in Canada

•Emerging generic market, < 5% generic penetration•1stIndian pharma company

USA

EU

CANADA

JAPAN

Global Manufacturing Strengths• cGMP compliant world-class API & Dosage Forms

manufacturing facilities across the globe• 7 manufacturing locations worldwide• API facilities -increasing vertical integration• Creating capacities for specialty products• New facilities added in cost advantageous geographies

USA Ireland Romani

a

Malaysia South Africa India

Nigeria

CIS

North America

Europe API

RoW

Asia

Global Sales (2009): US $ 1519Mn

Global Sales Split

Emerging54%

Others7%

Developed39%

FY 2005 FY 2009•Improving balance in market mix•Growth well spread across geographies•Positioned to leverage various market opportunities.

Evolution of Market Mix

Market Share of RanbaxyMarket Share of Ranbaxy

Global Markets Mix 2008Global Markets Mix 2008

54% & Emerging

The Company is currently ranked 2nd in the Indian pharmaceutical market with 4.98% market share (IMS, Oct-Dec’09).

Global sales in 2009 were USD 1,519 Mn (Rs. 73,441 Mn), De-growth of 9% over previous year. In Rupee terms, sales grew moderately by 1%. Sales during the Quarter recorded growth of 25% at USD 482 Mn (Rs. 22,699 Mn). Emerging markets accounted for 54% of sales during the year, while developed markets contributed 39%.

REVENUE AND PROFIT AFTER TAX

Key competitorsKey competitors

GlaxoSmithKline

RPG Enterprises

East India Pharmaceutical

Dr. Reddy's Laboratories

Cipla Ltd

Dabur India Ltd

Forecasts For 2010, the company forecast a 48% growth in net profit to

Rs460 crore from Rs311 crore in 2009, and a 6% rise in sales to around Rs7,800 crore.

“Ranbaxy’s overall numbers appear fine but their guidance for 2010 is disappointing,” said a Mumbai-based analyst with a foreign brokerage, asking not to be named as he’s not authorized to speak to the media.

“If they will have sales revenue from exclusive launches of generic versions of Valtrex and Flomax as well as Nexium supplies to AstraZeneca Plc in 2010, then why will growth in the year be only 6% on sales?”

The December quarter’s profit was backed by revenue from the exclusive launch of two major drugs in the US—generic versions of anti-herpes drug Valtrex and epilepsy medicine Trileptal—and a hold on costs in various markets, including in Europe

Ranbaxy Laboratories LimitedCorporate Office

Plot 90, Sector 32, Gurgaon -122001 (Haryana), INDIA

Ph: 91- 124- 4135000Fax: 91-124-4135001

Web site:- www.ranbaxy.com